Star Combo Pharma Ltd.
AASX:S660.14
AUD
0.00
(0.00%)
ISIN
AU0000004798
Return %
Stock
S&P 500
1Y
-30.00
14.20
3Y
27.27
81.12
5Y
-52.54
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Su Zhang
- Full Time Employees
- 30
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- 171-177 Woodpark Road Smithfield NSW Australia 2164
- IPO Date
- May 16, 2018
- Website
- starcombo.com.au
- Similar Companies
- Business
- Star Combo Pharma Limited (ASX: S66) is a clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapeutics for the treatment of metabolic and endocrine disorders. The company offers a pipeline of proprietary peptide therapeutics, including STAR-101, a dual GLP-1/GIP receptor agonist for obesity and type 2 diabetes; STAR-201, a long-acting growth hormone secretagogue for growth hormone deficiency; and STAR-301, a GIP receptor antagonist for the treatment of congenital hyperinsulinism; along with preclinical candidates targeting additional endocrine conditions. Star Combo Pharma operates primarily in the biotechnology sector, targeting global markets in endocrinology and metabolism with customers including pharmaceutical partners, clinical trial participants, and healthcare providers in Australia, the United States, and Europe. Founded in 2022 and headquartered in Melbourne, Australia, the company maintains research and development facilities in Australia and collaborates with contract manufacturing organizations internationally. In the past year, Star Combo Pharma completed a successful initial public offering on the ASX in late 2024, raising AUD 10 million to advance its Phase 1 clinical trials for STAR-101; entered a strategic research collaboration with a leading Australian university for peptide optimization; and announced the appointment of a new Chief Medical Officer with expertise in metabolic diseases to oversee pipeline expansion.